Skip to main content
. 2022 Feb 24;39(4):1810–1831. doi: 10.1007/s12325-022-02068-7

Fig. 5.

Fig. 5

a Mean (SE) number of Gd+ lesions and b percentage of patients free from Gd+ lesions. DRF diroximel fumarate, GA glatiramer acetate, Gd+ gadolinium-enhancing, IFN interferon